METHOD OF TREATING CHILDREN WITH MANIFESTATION OF LINGERING JAUNDICE IN NEONATAL PERIOD Russian patent published in 2011 - IPC A61K9/02 A61K31/7016 A61K31/522 A61P1/16 A61K35/413 A61P31/22 A61K31/575 A61P31/04 

FIELD: medicine.

SUBSTANCE: invention relates to medicine and is intended for treatment of lingering versions of jaundice course in newborn babies. UDCA preparations are administered in dose 20-30 mg/kg per day, therapy is carried out for not less than 3 months. Viferon suppositories are administered rectally. Day dose is 50 thousand units/kg. Scheme of introduction is 10 days-daily, after that every second day from 3 to 9-12 months. Cytomegalovirus is suppressed with application of medication aciclovir-akri and its analogues zovirax, valtrex for 21-30 days. To suppress causing agents of mycoplasmosis, ureaplasmosis and chlamidiosis, preparations from group of macrolids rovamicin and sumamed are administered. Scheme is: rovamicin in dose 100 thousand units/kg for 7 days, after that, sumamed with a single dose 10 mg/kg once, according to discontinuous scheme 1 time per week, for 3 weeks. Additionally applied are medications, enhancing phagocytocis: licopid, polyoxydonium, solution of dimephosphone in age doses.

EFFECT: method makes it possible to reduce treatment terms and avoid complications.

2 ex